News | April 10, 2021
Aurore to merge with Solara in an all-stock transaction
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
